Free Trial

CorMedix (CRMD) Competitors

CorMedix logo
$11.50 -0.12 (-1.03%)
Closing price 04:00 PM Eastern
Extended Trading
$11.64 +0.14 (+1.17%)
As of 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRMD vs. KYMR, MOR, HCM, RARE, ALVO, AMRX, MIRM, CPRX, ARWR, and IBRX

Should you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include Kymera Therapeutics (KYMR), MorphoSys (MOR), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Alvotech (ALVO), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Arrowhead Pharmaceuticals (ARWR), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

CorMedix vs. Its Competitors

Kymera Therapeutics (NASDAQ:KYMR) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

In the previous week, Kymera Therapeutics had 3 more articles in the media than CorMedix. MarketBeat recorded 5 mentions for Kymera Therapeutics and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.55 beat Kymera Therapeutics' score of 0.76 indicating that CorMedix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kymera Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CorMedix
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

CorMedix has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera Therapeutics$47.07M63.43-$223.86M-$3.10-14.79
CorMedix$43.47M17.94-$17.93M$0.2252.27

Kymera Therapeutics currently has a consensus price target of $59.11, indicating a potential upside of 28.92%. CorMedix has a consensus price target of $17.14, indicating a potential upside of 49.07%. Given CorMedix's higher possible upside, analysts clearly believe CorMedix is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kymera Therapeutics
0 Sell rating(s)
1 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
3.05
CorMedix
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.88

CorMedix has a net margin of 20.81% compared to Kymera Therapeutics' net margin of -409.07%. CorMedix's return on equity of 22.57% beat Kymera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kymera Therapeutics-409.07% -30.11% -25.65%
CorMedix 20.81%22.57%17.02%

34.2% of CorMedix shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 5.3% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Kymera Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500.

Summary

CorMedix beats Kymera Therapeutics on 9 of the 17 factors compared between the two stocks.

Get CorMedix News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRMD vs. The Competition

MetricCorMedixMED IndustryMedical SectorNASDAQ Exchange
Market Cap$788.12M$3.06B$5.70B$9.48B
Dividend YieldN/A2.37%4.59%3.99%
P/E Ratio52.2820.7327.9019.95
Price / Sales17.94321.12442.19102.72
Price / CashN/A43.2336.5558.97
Price / Book8.218.308.635.90
Net Income-$17.93M-$55.19M$3.24B$258.42M
7 Day Performance3.88%5.07%3.22%1.94%
1 Month Performance-26.84%17.61%10.72%12.02%
1 Year Performance141.09%7.03%34.94%20.81%

CorMedix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRMD
CorMedix
2.9016 of 5 stars
$11.50
-1.0%
$17.14
+49.1%
+140.6%$788.12M$43.47M52.2830Positive News
KYMR
Kymera Therapeutics
3.1714 of 5 stars
$44.90
+0.9%
$59.11
+31.7%
+6.8%$2.92B$47.07M-14.48170
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
HCM
HUTCHMED
2.8261 of 5 stars
$16.23
+1.2%
$19.00
+17.1%
-7.0%$2.83B$630.20M0.001,811Positive News
Analyst Forecast
RARE
Ultragenyx Pharmaceutical
4.3469 of 5 stars
$29.23
-0.9%
$83.64
+186.2%
-38.0%$2.76B$560.23M-4.971,294Upcoming Earnings
High Trading Volume
ALVO
Alvotech
2.8765 of 5 stars
$8.90
+4.5%
$18.00
+102.2%
-22.4%$2.68B$585.60M24.051,032
AMRX
Amneal Pharmaceuticals
3.2894 of 5 stars
$8.42
+1.1%
$11.60
+37.8%
+8.6%$2.64B$2.79B-210.458,100
MIRM
Mirum Pharmaceuticals
3.9527 of 5 stars
$53.28
+1.2%
$65.50
+22.9%
+32.0%$2.64B$336.89M-33.09140
CPRX
Catalyst Pharmaceuticals
4.9134 of 5 stars
$21.62
-0.9%
$32.83
+51.9%
+22.8%$2.64B$491.73M13.7780News Coverage
Positive News
ARWR
Arrowhead Pharmaceuticals
3.8862 of 5 stars
$18.61
+1.6%
$43.71
+134.9%
-44.7%$2.57B$545.21M-13.29400Positive News
IBRX
ImmunityBio
2.0236 of 5 stars
$2.90
+3.2%
$12.25
+322.4%
-47.1%$2.56B$31.22M-5.00590

Related Companies and Tools


This page (NASDAQ:CRMD) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners